SinoMab BioScienceの資産のリターン
SinoMab BioScienceの資産のリターン は何ですか。
SinoMab BioScience Limitedの資産のリターン は-23.63%です。
資産のリターン の定義は何ですか。
資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
HKSEのセクタHealth Careにおける資産のリターン の企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似の資産のリターン
- Nemaura Medicalの資産のリターン は-23.74%です。
- RA International PLCの資産のリターン は-23.72%です。
- Spineway Societe Anonymeの資産のリターン は-23.71%です。
- Cullen Resourcesの資産のリターン は-23.70%です。
- Alpha HPAの資産のリターン は-23.70%です。
- Kaleyra Incの資産のリターン は-23.69%です。
- SinoMab BioScienceの資産のリターン は-23.63%です。
- The Conygar Investment PLCの資産のリターン は-23.63%です。
- BiVictriX Therapeutics plcの資産のリターン は-23.62%です。
- Innovative Designsの資産のリターン は-23.62%です。
- Integra Garments and Textilesの資産のリターン は-23.59%です。
- Feedback plcの資産のリターン は-23.59%です。
- Netscout Systems Incの資産のリターン は-23.55%です。